^
1m
Enrollment closed • Enrollment change • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
CD7 expression
|
WU CART 007
3ms
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial. (PubMed, Res Sq)
WU-CART-007 at the RP2D demonstrated a high response rate in patients with relapsed/refractory T-ALL/LBL and has the potential to provide a new treatment option. ClinicalTrials.gov registration: NCT04984356.
P1/2 data • Journal
|
CD7 (CD7 Molecule)
|
WU CART 007
3ms
WU-CART-007 1001: A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (clinicaltrials.gov)
P1/2, N=29, Completed, Wugen, Inc. | Active, not recruiting --> Completed | N=44 --> 29 | Trial completion date: Aug 2026 --> Jun 2024 | Trial primary completion date: May 2026 --> Jun 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
WU CART 007
4ms
New P2 trial • CAR T-Cell Therapy • Minimal residual disease
|
WU CART 007
11ms
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
WU CART 007
12ms
Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) (TCT-ASTCT-CIBMTR 2024)
Most (72%; 13) pts had G1-2 CRS events; a single G3 CRS event was reported which resolved within 72 hours after receiving tocilizumab, steroids, and low-dose vasopressors. WU-CART-007 has demonstrated an acceptable safety profile and preliminary evidence of anti-leukemic activity. This program advances CAR-T cell therapy in heavily pre-treated patients with R/R T-ALL/LBL.
P1/2 data • CAR T-Cell Therapy • IO biomarker
|
CCR7 (Chemokine (C-C motif) receptor 7) • CD7 (CD7 Molecule)
|
Actemra IV (tocilizumab) • WU CART 007
12ms
Enrollment closed
|
WU CART 007
1year
Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) (ASH 2023)
Two different LDC regimens have been tested: standard LDC (fludarabine 30 mg/m2/day x 3 days and cyclophosphamide 500 mg/m2/day x 3 days), and enhanced LDC (eLDC; fludarabine 30 mg/m2/day x 4 days and cyclophosphamide 1000 mg/m2/day x 3 days)...Most (72%; 13/18) pts had G1-2 CRS events; a single G3 CRS event was reported which resolved within 72 hours after receiving tocilizumab, dexamethasone, and low-dose vasopressors...This program advances CAR-T cell therapy in heavily pre-treated patients with R/R T-ALL/LBL. Enrollment is ongoing.
P1/2 data • CAR T-Cell Therapy • IO biomarker
|
CCR7 (Chemokine (C-C motif) receptor 7) • CD7 (CD7 Molecule)
|
cyclophosphamide • dexamethasone • fludarabine IV • Actemra IV (tocilizumab) • WU CART 007
1year
Enrollment open • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
CD7 expression
|
WU CART 007
over1year
PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL) (EHA 2023)
All patients receive a 3-day lymphodepletion regimen consisting of fludarabine and cyclophosphamide, followed by a single dose of WU- CART-007...Most (86%; 7/8) pts had G1-2 CRS events; a single G3 CRS event was reported which resolved within 24 hours after receiving tocilizumab, dexamethasone and low dose vasopressors... WU-CART-007 has demonstrated an acceptable safety profile and preliminary evidence of anti-leukemic activity. in a subset of patients. This program advances CAR-T cell therapy in heavily pre-treated patients with R/R T-ALL/LBL.
P1/2 data • CAR T-Cell Therapy
|
cyclophosphamide • dexamethasone • fludarabine IV • Actemra IV (tocilizumab) • WU CART 007
over1year
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov)
P1, N=48, Not yet recruiting, Washington University School of Medicine | Trial completion date: Sep 2025 --> Jan 2026 | Initiation date: Mar 2023 --> Jul 2023 | Trial primary completion date: Sep 2025 --> Jan 2026
Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
CD7 expression
|
WU CART 007
almost2years
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov)
P1, N=48, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jun 2025 --> Sep 2025 | Initiation date: Dec 2022 --> Mar 2023 | Trial primary completion date: Jun 2025 --> Sep 2025
Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
CD7 expression
|
WU CART 007
2years
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies (clinicaltrials.gov)
P1, N=48, Not yet recruiting, Washington University School of Medicine | Trial completion date: Feb 2025 --> Jun 2025 | Initiation date: Aug 2022 --> Dec 2022 | Trial primary completion date: Feb 2025 --> Jun 2025
Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
CD7 expression
|
WU CART 007
over2years
New P1 trial • CAR T-Cell Therapy
|
CD7 (CD7 Molecule)
|
CD7 expression
|
WU CART 007
almost3years
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL) (ASH 2021)
All patients will receive a single infusion of WU-CART-007 cells on day 1 following a lymphodepleting conditioning therapy consisting of fludarabine and cyclophosphamide on days -5 to -3. Response will be assessed on Cycle 1 Day 28 (± 1 days), and at Months 3, 6, 12, and 24, by bone marrow aspirate and biopsy and PET/CT if indicated. Response will be defined as per modified NCCN Guidelines Version 2.2020.
Clinical • P1/2 data • CAR T-Cell Therapy • IO biomarker
|
CD7 (CD7 Molecule)
|
CD7 overexpression
|
cyclophosphamide • fludarabine IV • WU CART 007
3years
Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies (ASH 2021)
Conclusions These preclinical studies support the use of WU-CART-007 in clinical trials and highlight the potential of WU-CART-007 to be a well-tolerated and active therapy for patients with CD7+ T-cell malignancies. A first in human Phase 1/2 trial in patients with R/R T-ALL/LBL is currently open for enrollment (NCT# 04984356).
CAR T-Cell Therapy
|
CD34 (CD34 molecule) • CD7 (CD7 Molecule)
|
WU CART 007